Homepage ASDReports
Your Cart Is Empty
Page 1 of 1 | 1 |
Report title   (click to sort results)

US$3,500.00
Aug 2010

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

GBI Research’s Therapeutic Analysis report, “Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$2,000.00
Jul 2010

Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016

Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 201GlobalData, the industry analysis specialist’s new report, “Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. The report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.


 

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$2,000.00
Apr 2010

Urinary Tract Infections - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Urinary Tract Infections (UTI) - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global urinary tract infections market. The report identifies the key trends shaping and driving the global urinary tract infections market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global urinary tract infections sector.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$2,000.00
Apr 2010

Benign Prostatic Hyperplasia - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Benign Prostatic Hyperplasia– Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global benign prostatic hyperplasia market. The report identifies the key trends shaping and driving the global benign prostatic hyperplasia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global benign prostatic hyperplasia sector.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$2,000.00
Apr 2010

Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Urinary Incontinence– Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global urinary incontinence market. The report identifies the key trends shaping and driving the global urinary incontinence market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global urinary incontinence sector.


 

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$4,850.00
Nov 2009

Renal Disease Treatments: Products and Therapies

REPORT HIGHLIGHTS

  • The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expected to increase to $32.8 billion in 2013. The compound annual growth rate (CAGR) for the 5-year period is projected at 11.5%.
  • The pharmaceuticals segment dominated the market at $17.6 billion in 2008. That figure is expected to increase to $30.2 billion in 2013, for a CAGR of 11.5%.
  • The devices segment of the market generated $1.48 billion in sales in 2008 and is projected to increase to $2.5 billion in 2013, for a CAGR of 11.4%.
Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$1,495.00
Jul 2009

Benign Prostatic Hyperplasia - Therapy Area Pipeline Report

Life Science Analytics', Kidneys and Genito-Urinary System Benign Prostatic Hyperplasia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of benign prostatic hyperplasia drugs by company and by stage as well as a summary of the latest news and developments in this area.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$1,495.00
Jul 2009

Diabetic Nephropathy - Therapy Area Pipeline Report

Life Science Analytics', Kidneys and Genito-Urinary System Diabetic Nephropathy contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of diabetic nephropathy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$1,495.00
Jul 2009

Erectile Dysfunction - Therapy Area Pipeline Report

Life Science Analytics', Kidneys and Genito-Urinary System Erectile Dysfunction contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of erectile dysfunction drugs by company and by stage as well as a summary of the latest news and developments in this area.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$1,495.00
Jul 2009

Hyperphosphatemia - Therapy Area Pipeline Report

Life Science Analytics', Kidneys and Genito-Urinary System Hyperphosphatemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of hyperphosphatemia drugs by company and by stage as well as a summary of the latest news and developments in this area.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$1,495.00
Jul 2009

Kidney Stones - Therapy Area Pipeline Report

Life Science Analytics', Kidneys and Genito-Urinary System Kidney Stones contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of kidney stones drugs by company and by stage as well as a summary of the latest news and developments in this area.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$1,495.00
Jul 2009

Overactive Bladder - Therapy Area Pipeline Report

Life Science Analytics', Kidneys and Genito-Urinary System Overactive Bladder contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of overactive bladder drugs by company and by stage as well as a summary of the latest news and developments in this area.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$1,495.00
Jul 2009

Urinary Incontinence - Therapy Area Pipeline Report

Life Science Analytics', Kidneys and Genito-Urinary System Urinary Incontinence contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of urinary incontinence drugs by company and by stage as well as a summary of the latest news and developments in this area.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$11,400.00
Apr 2009

Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth

BPH is a chronic urological condition involving the non-cancerous enlargement of the prostate affecting over 15 million men across the seven major markets. The market for BPH drugs that aim to alleviate the symptoms and reduce prostate size was worth $3.7bn in 2008. The BPH market is expected to continue growing over the next 10 years driven by the launch of new improved treatments.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$3,800.00
Apr 2009

Stakeholder Opinions: Urinary Tract Infections Growing resistance rates bring opportunities for both new and old drugs

IUrinary tract infections (UTIs) include infections of the kidneys, ureters, and bladder. Escherichia coli is the major UTI pathogen, with emerging extended-spectrum beta-lactamase (ESBL)-producing strains proving particularly difficult to treat. Bacterial resistance to the most commonly used UTI drugs is growing, highlighting the unmet need and opportunity for novel therapies.

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

US$15,200.00
Dec 2007

Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth

The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine), GSK's Vesicare (solifenacin), and Novartis' Enablex (darifenacin).

Order NowAdd to cart  |   More InformationMore information  |   Tell-a-FriendTell a friend

Page 1 of 1 | 1 |

   ASD Reports - © 2008-2010 - contact us - terms & conditions - privacy policy